PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

CEO

ISIN

US71715X2036

Listings

0 Comments

Share your thoughts

FAQ

What is PharmaCyte Biotech stock price today?▼

The current price of PMCB.BOATS is $0.44 USD — it has increased by +0% in the past 24 hours. Watch PharmaCyte Biotech stock price performance more closely on the chart.

What is PharmaCyte Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange PharmaCyte Biotech stocks are traded under the ticker PMCB.BOATS.

What is PharmaCyte Biotech market cap?▼

Today PharmaCyte Biotech has the market capitalization of 4.72M

When is the next PharmaCyte Biotech earnings date?▼

PharmaCyte Biotech is going to release the next earnings report on December 16, 2026.

What is PharmaCyte Biotech revenue for the last year?▼

PharmaCyte Biotech revenue for the last year amounts to 0 USD.

What is PharmaCyte Biotech net income for the last year?▼

PMCB.BOATS net income for the last year is -23.21M USD.

In which sector is PharmaCyte Biotech located?▼

PharmaCyte Biotech operates in the Other sector.

When did PharmaCyte Biotech complete a stock split?▼

The last stock split for PharmaCyte Biotech was on July 12, 2021 with a ratio of 1:1500.